SEVILLE, Spain — Treatments for uveitic macular edema, including systemic and local options, were among the topics debated at the Congress on Controversies in Ophthalmology.
Macular edema develops in up to 30% of uveitic eyes and is the most prevalent factor contributing to visual impairment in patients with uveitis.
Management refers to two clinical scenarios: treating the acute phase and preventing long-term recurrences.
For local treatment, there are currently two options for the acute phase, periocular triamcinolone or Ozurdex (dexamethasone intravitreal implant, AbbVie). Iluvien